← Oncology Approval Tracker

FDA DECISION ·

Ibrance + aromatase inhibitor

palbociclib plus an aromatase inhibitor · Pfizer

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adds pre- and perimenopausal women to initial endocrine-based use with an aromatase inhibitor in HR-positive, HER2-negative advanced or metastatic breast cancer.

LAMPGEN ANALYSIS

Why it matters

The expanded population brings this labeled regimen to additional patients with earlier menopausal status.

What research teams should watch

Document menopausal status, the aromatase inhibitor, and any required ovarian suppression in the regimen plan.

PRIMARY RECORDS

Sources